Forkheadbox protein 3 (FOXP3), initially identified as a key transcription factor for regulatory T cells (Treg cells), was also expressed in many tumors including pancreatic ductal adenocarcinoma (PDAC). However, its role in PDAC progression remains elusive. In this study, we utilized 120 PDAC tissues after radical resection to detect cancer-FOXP3 and Treg cells by immunohistochemistry and evaluated clinical and pathological features of these patients. Cancer-FOXP3 was positively correlated with Treg cells accumulation in tumor tissues derived from PDAC patients. In addition, high cancer-FOXP3 expression was associated with increased tumor volumes and poor prognosis in PDAC especially combined with high levels of Treg cells. Overexpression of cancer-FOXP3 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromised or Treg cell-depleted mice. Furthermore, CCL5 was directly trans-activated by cancer-FOXP3 and promoted the recruitment of Treg cells from peripheral blood to the tumor site in vitro and in vivo. This finding has been further reinforced by the evidence that Treg cells recruitment by cancer-FOXP3 was impaired by neutralization of CCL5, thereby inhibiting the growth of PDAC. In conclusion, cancer-FOXP3 serves as a prognostic biomarker and a crucial determinant of immunosuppressive microenvironment via recruiting Treg cells by directly trans-activating CCL5. Therefore, cancer-FOXP3 could be used to select patients with better response to CCL5/CCR5 blockade immunotherapy.
INTRODUCTION
Characterized by rapid progression, pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumor with a 5-year survival rate o 5%. 1 The poor prognosis results from the early onset of invasion and metastasis, as well as lack of effective therapies. To improve PDAC survival rate, novel treatment modalities are urgently needed. In recent studies, immunotherapy has shown a promising effect on several solid tumors.
2-4 PDAC tissues were initially defined as immune privileged milieu with rare effector T cells. 5 Recently, several data from primary human tumor samples demonstrated that efficient cytotoxic (CD8 + ) T cells accumulated within the PDAC microenvironment and maintained the activity of secreting IFN-r. 6, 7 The failure to control tumor growth may derive from multiple immunosuppressive mechanisms rather than deficiency of adaptive immunity. 8 Infiltration of CD4 + CD25 + FOXP3 + regulatory T cells (Treg cells) is a major cause of immunologic tolerance and associated with poor prognosis in PDAC patients, 9 but the mechanism for Treg cells infiltration in PDAC remains unclear.
Forkheadbox protein 3 (FOXP3) is a key transcription factor regulating development and function of Treg cells 10 and its expression has been reported in several tumors such as melanoma, pancreatic cancer and breast cancer (cancer-FOXP3, referred as c-FOXP3 hereafter). 11 However, the functions of c-FOXP3 are complicated and cell type dependent. 12 C-FOXP3 has been initially defined as a tumor suppressor in breast, prostate and ovarian cancers through repressing the expression of several oncogenes and activating tumor-suppressor genes. On the contrary, c-FOXP3 has been identified as a biomarker of poor prognosis in urinary bladder cancer, non-small cell lung cancer, esophageal cancer and melanoma. 13 In PDAC, a pilot study reported that c-FOXP3 was expressed in PDAC cells and suppressed the function of effector CD4 +
CD25
-T cells by secreting transforming growth factor-β (TGF-β) in vitro.
14 However, this pilot study is based on a small number of patients without follow-up (N = 39) and limited to in vitro analysis. The clinical significance and function of c-FOXP3 in PDAC in vivo need to be elucidated.
In this study, we defined c-FOXP3 as a biomarker of poor prognosis based on the 120 samples of PDAC after radical resection. Intriguingly, c-FOXP3 was highly associated with the numbers of FOXP3 + Treg cells, inspiring us to identify the possibility and mechanism of c-FOXP3 in recruiting Treg cells infiltration, which could help in optimizing the strategy of immunotherapy in PDAC.
RESULTS

FOXP3 protein is overexpressed in human PDAC specimens and cell lines
A pilot study discovered the expression of FOXP3 in PDAC samples (defined as c-FOXP3), but its clinical significance was unclear. To better understand the role of c-FOXP3 in PDAC progression, immunohistochemistry was conducted to determine the FOXP3 expression in tumor tissues of 120 patients with PDAC. Normal pancreatic tissue, as well as the specimens of pancreatic tumors serous cystadenoma, pancreatic intraepithelial neoplasia and pancreatic neuroendocrine tumor was used as negative control. The specimen of the spleen was used as positive control. FOXP3 expression was detected in PDAC samples but not found in other samples ( Figure 1a ). In addition, normal pancreatic ductal epithelium cells adjacent to PDAC tissues were found negative for FOXP3 expression (Figure 1b) . Intriguingly, robust expression of FOXP3 protein was found in both cytoplasm and nucleus of 76 PDAC tissues and was significantly correlated with shorter overall survival (OS; median time, 15 and 24 months, P o0.001) and relapse-free survival (RFS; median time, 9 and 15 months, P = 0.0012; Figures 1c and d) , suggesting that c-FOXP3 is a biomarker for poor prognosis of PDAC. FOXP3 expression was detected in four human PDAC cell lines, but showed negative in a normal pancreatic ductal epithelial cell line, which is consistent with the data from the tissue samples (Supplementary Figure 1A) . c-FOXP3 affecting tumor size in PDAC involves Treg cells accumulation To identify the role of c-FOXP3 in the progression of PDAC, we analyzed the correlation between c-FOXP3 and several pathological parameters of PDAC patients. Interestingly, the patients with high c-FOXP3 showed larger tumor volumes than those with low c-FOXP3 (Figure 3a) , whereas other parameters (including age, sex, lymphnode metastasis, pTNM stage and CA19-9) showed no significant differences (Supplementary Table 1 ). To identify the mechanism of c-FOXP3-induced tumor growth, we first evaluated whether c-FOXP3 directly affected the growth of PDAC. The stable cell lines with overexpressed or downexpressed FOXP3 were established (Supplementary Figure 1B) . Apoptosis analysis, cell cycle analysis and Edu incorporation assay were performed, but Figure 3D ). Therefore, we propose that c-FOXP3-induced tumor growth is associated with the immunosuppressive effect. The hypothesis was supported by our data that Treg cells numbers in the c-FOXP3-interfered group varied from 4.5 to 9.6%, whereas that in the control group varied from 5.3 to 13.9% (P o 0.05; Figure 3d ). Similarly, Treg numbers in the c-FOXP3 overexpression group varied from 7.2 to 16.3%, whereas those in the control group varied from 5.8 to 9.3% (P o0.05; Supplementary Figure 3E Figure 4F) and the total numbers of recruited Treg cells by pancreatic cancer cell lines were evaluated using the same method described above (Supplementary Figure 4G ). In consistence with the results in the peripheral blood mononuclear cells recruitment assay, the expression level of c-FOXP3 was positively correlated to the numbers of Treg cells recruited to the lower chamber.
Furthermore, Treg cells recruitment was evaluated in vivo. We established an orthotropic implantation model in nude mice by injecting human pancreatic cancer cell lines of Panc-1-pLV-FOXP3 or Panc-1-pLV-Control into pancreas. The implanted nude mice were treated with human peripheral blood mononuclear cells injection through tail vein once a week. Tumors were harvested for analysis after 6 weeks (Figure 4d ). Flow cytometry analysis showed that Treg cells infiltration in low-FOXP3 tumors (1.9 to 11.0%) is much lower than that in high-FOXP3 tumors (3.2 to 26.5%; P o 0.05; Figure 4e ). This is consistent with the results from in vitro experiments. In conclusion, c-FOXP3 has a drastic chemoattractant effect on Treg cells.
CCL5 expression correlates with c-FOXP3 levels in PDAC After the recruitment of Treg cells by c-FOXP3 has been identified in vitro and in vivo, we try to find out the chemokines mediating the recruitment. Among the major recruitment-associated chemokines, CCL5 was found to change most significantly on the transcription level in response to Figure 6A) . After 28 days, all mice were killed for tumor harvest except for the one in the intratumoral group died after surgery. Flow cytometry analysis of the single-cell suspension indicated that Treg cells infiltration was decreased by blocking CCL5 in both Pan02-pLV-Control groups and Pan02-pLV-FOXP3 groups but has a stronger effect on the Pan02-pLV-FOXP3 groups (Figures 6d and e, Supplementary Figures 6B and C) . Apoptotic CD8 + T cells were also decreased along with the decreased Treg cells (Figure 6f, Supplementary Figure 6D ). In addition, the average tumor volumes of the CCL5 antibody-treated groups were smaller than those of the IgG-treated groups. The growth inhibition rate in the Pan02-pLV-FOXP3 groups was more significant than that in the Pan02-pLV-Control groups (Figure 6g, Supplementary  Figure 6E ). In summary, CCL5 is involved in the recruitment of Treg cells by c-FOXP3, thereby promoting tumor growth in an immunosuppressive environment.
The role of cancer-FOXP3 in PDAC X Wang et al
DISCUSSION
It is well established that the immunosuppression caused by the accumulation of Treg cells in the tumor environment is a key factor for the poor prognosis in PDAC patients. [15] [16] [17] [18] Recently, the discovery of FOXP3, a Treg cells marker, in a variety of cancers inspired the investigation to distinguish the function of c-FOXP3 from that of Treg-FOXP3. In this study, we identified that c-FOXP3 is critical to recruit Treg cells in the microenvironment of PDAC and CCL5, which is directly trans-activated by c-FOXP3, mediates the recruitment of FOXP3 + T cells. c-FOXP3 expression was initially identified in a cohort of 39 tissue samples from PDAC patients, 14 but their study did not reveal the link between c-FOXP3 and pathological consequences because of the different clinical characteristics -4MUT) vectors. pGL3-p21-promoter was used as positive control. After 48 hours, firefly and renilla luciferase activities were measured using the Dual-Luciferase Reporter assay (Promega, Madison, WI, USA) and the ratio was determined (*P o0.05, by Student's t-test). The experiment was performed in triplicate and repeated three times with the same results.
In this cohort, we discovered that c-FOXP3 was overexpressed in PDAC tissues compared with normal pancreatic tissues and other types of pancreatic tumor. We also demonstrated that high c-FOXP3 predicted a poor prognosis in PDAC. In the tumor sections stained for FOXP3, we detected FOXP3 + tumor-infiltrating lymphocytes representing Treg cells, which is consistent with previous reports. 14, 15 Intriguingly, the higher expression of c-FOXP3, the more Treg cells were found around the tumor + pancreatic cancer cells could directly inhibit the activity of effector T cells by secreting inhibitory cytokines. 20 In cholangiocarcinoma, c-FOXP3 also functions to promote invasion and metastasis of cancer cells. 21 Our ongoing study is recruiting PDAC patients in late stages and investigates the role of c-FOXP3 in metastasis of PDAC.
Previous studies suggested that c-FOXP3 directly boosted cell growth in other types of cancers. 22 To investigate the mechanism of c-FOXP3 in promoting tumor growth, we first conducted a series of in vitro analysis to exclude the possibility that c-FOXP3 directly influenced cell growth. Then, we constructed cell lines with stable c-FOXP3 knockdown and planted them into mice models in different immune states. Data showed that knockdown of c-FOXP3 decreased the PDAC tumor size in the immunocompetent mice but not in the immunocompromised mice, suggesting that c-FOXP3-induced tumor growth is dependent on the immune system. Besides, c-FOXP3 did not promote tumor growth in Treg cell-depleted mice and it was only associated with tumor size when Treg cells number is high in PDAC samples. Taken together, Treg cells are involved in the tumor growth promoted by c-FOXP3 in PDAC.
Previous reports addressed the mechanism of how Treg cells affected tumor progression. In ovarian cancer, Treg cells infiltration led to poor prognosis by promoting angiogenesis in the tumor microenvironment. 23 Moreover, Treg cells were found an anti-inflammatory role by inhibiting effector T cells, which may further promote immune escape. 24 It was also reported that tumor-infiltrating Treg cells could induce apoptosis of effector T cells through killer molecules such as FasL, Granzyme B and TGF-β. [25] [26] [27] In this study, we showed that knockdown of c-FOXP3 led to reduction of Treg cells and decreased the apoptosis of CD8 As the transwell system avoided the direct contact between PDAC cell lines and Treg cells, we proposed that the recruitment is mediated by the chemokines triggered by c-FOXP3. Several cytokines have been recognized as important media for Treg cells recruitment. 31, 32 CCL28 was found to have a role in hypoxiainduced Treg cells recruitment in ovarian cancer. 23 Meanwhile, it has been revealed that Treg cells were recruited through the pathway of TGF-β-miR-34a-CCL22 in hepatocellular carcinoma.
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CCL22 was discovered in Treg cells recruitment in breast cancer, which could be diminished by blocking CCR4. 34 In pancreatic cancer, knockdown of CCR5 resulted in suppression of tumor growth and significant decrease of Treg cells in the tumor microenvironment, indicating that the CCL5/CCR5 pathway mediated the infiltration of Treg cells. 35 In this study, we discovered for the first time that CCL5 was positively correlated with c-FOXP3 and directly trans-activated by c-FOXP3 in PDAC cells. When the CCL5/CCR5 signaling pathway was blocked by the CCL5 antibody in vitro and in vivo, Treg cells recruitment to the tumor microenvironment was reduced. The reduction rate is more significant in the c-FOXP3 high expression group, indicating that CCL5 is involved in the recruitment of Treg cells induced by c-FOXP3. Although CCR5 was also expressed in the effector T cells, its expression level was lower than in Treg cells. 36 In combination with the finding that Treg cells exhibited a greater chemotactic response toward CCR5 than the effector T cells, 37 it suggested a more important role of the CCL5/CCR5 pathway on Treg cells recruitment than the effector T cells in PDAC. Notably, the recruitment of Treg cells may not be solely driven by CCL5. Preliminary evidence suggested that other chemokine receptors, such as CCR4, CCR10 and CXCR4, were discovered on the cell surface of Treg cells. 38, 39 Further investigation is needed to understand the synergistic effect of different chemokines in the recruitment of Treg cells in PDAC.
Treg cells depletion is a promising strategy to enhance antitumor immune response. [40] [41] [42] Recently, a pilot clinical study showed a favorable response targeting FOXP3 + CD4 + Treg cells depletion in lung and esophageal carcinoma. 43 However, unselective depletion of Treg cells may result in severe autoimmune disorders, impeding the clinical translation of this strategy. As CCL5 has been identified as a key chemokine for Treg cells infiltration in PDAC, it is more reasonable to develop tumor immunotherapy via blocking CCL5/CCR5 [44] [45] [46] to reduce the Treg cells infiltration in the local site of PDAC. Combined with our findings, we propose that the patients with high c-FOXP3 expression may respond better to the strategy of CCL5/CCR5 blockade.
Recent evidence showed that multiple immunosuppressive compositions exist in the PDAC microenvironment including M2 (CD163) macrophages, the checkpoint signaling (PD-L1 and CTLA-4) and FOXP3 + Treg cells, and combined absence of the immunosuppressive markers defined a subtype of PDAC with improved prognosis. As a single checkpoint inhibitor achieved only modest effect in the treatment of PDAC, 47, 48 the combined blockade of immunosuppressive cells infiltration and the checkpoint signaling should be a promising strategy to better control PDAC.
It should be noted that there are several limitations for this study. First, to better understand the relationship between FOXP3 + tumor cells and FOXP3 + Treg cells, we have to select sufficient tissues for calculating the numbers of Treg cells. Therefore, all the samples were from patients with radical resection. Thus, the role of c-FOXP3 in metastatic pancreatic cancer need to be further defined. Second, the interaction of c-FOXP3 and Treg cells should be complicated and organ specific. For instances, c-FOXP3 showed inverse correlation to the Treg cells numbers in colorectal cancer but no correlation to those in scirrhous gastric carcinoma, 49 suggesting that the present findings were limited to pancreatic cancer.
In summary, we demonstrated that c-FOXP3 recruits 
Mice
Female SCID mice, nude mice and C57BL/6 mice of 4 weeks were used in animal experiments. All mice were maintained in the specific pathogenfree conditions and animal experiment procedures were approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital, in compliance with the principles and procedures of the NIH Guide for the Care and Use of Laboratory Animals. All groups were randomly divided. The CD25 antibody or the isotype control (0.5 mg per mouse, PC61, BioXcell, West Lebanon, NH, USA) was injected on days -2, 1 and 21 following the previous literature with modifications. 18 The CCL5 antibody or the isotype control (20 μg intratumorally per mouse, R&D Systems, Minneapolis, MN, USA) was injected twice a week. Harvested tumors were processed into the single-cell suspension with 1 mg/ml collagenase, 2.5 U/ml hyaluronidase and 0.1 mg/ml DNase. Details were shown in the Supplementary materials and methods.
Immunohistochemistry and immunofluorescence PDAC specimens were processed with formalin fixation, paraffin embedding and sectioned to 5 μm in thickness. Immunohistochemistry was performed with a standard protocol. Immunofluorescence was performed with frozen samples. Antibodies used are listed in Supplementary Table 3 . Details were shown in the Supplementary materials and methods.
Quantification of FOXP3 + T cells
Immunohistochemistry for FOXP3 + T cells was performed using standard procedures. Treg cells were counted under microscopy. Ten high-power fields (at × 40 magnification) were randomly selected from each specimen for digital photographs in area of 0.0625 mm 2 . Total numbers of lymphoid infiltrates and Treg cells in each field were counted manually by two investigators who did not know the clinical pathological characteristics and outcomes of patients.
Treg cells recruitment in vitro
Treg cells/peripheral blood mononuclear cells were placed in the upper chamber of the transwell and pancreatic cancer cells were placed in the lower chamber. After 24-h co-culture, cells in the lower chamber were collected and analyzed by flow cytometry for Treg cells population.
Western blot
Total protein was extracted with sodium dodecyl sulfate lyses buffer containing the proteinase inhibitors cocktail (Sigma, St Louis, MO, USA). Electrophoresis was performed as described in a standard protocol. Antibodies used are listed in Supplementary Table 3 . Details were shown in the Supplementary materials and methods.
Chromatin immunoprecipitation
ChIP assay was performed according to the manufacturer's instruction of a commercial kit (Millipore Corp., Bedford, MA, USA). PCR primers were listed in Supplementary Table 4 .
Quantitative real-time PCR Total RNA was extracted with TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA was prepared by reverse-transcription as standard protocol described, followed by quantitative real-time PCR. Primers were listed in Supplementary Table 4 .
Enzyme-linked immunosorbent assay PDAC cell lines (1 × 10 7 cells) were cultured for 72 h and the conditioned media collected after centrifugation at 700 g for 5 min at 4°C. CCL5 protein was quantified using human CCL5 ELISA kit (R&D Systems) according to the manufacturer's instructions.
Statistical analysis
Statistical analyses were performed with SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA). Paired/unpaired Student's t-test, one-way analysis of variance test, Spearman rank correlation coefficient test, χ 2 tests, Kaplan-Meier survival curves and log-rank test were performed. P o0.05 was considered significant.
